Receptor Tyrosine Kinases

1 Drug classified under this drug class

Non-Receptor Tyrosine Kinases Inhibitor, Receptor Tyrosine Kinases. Nintedanib (As Esliate) 100 mg, 150 mg.
CAPS.: 100mg × 30,60, 150mg × 60. Conduct liver funct. tests prior to init. tmt and a preg. test in females of reproduce. potent. prior to init. tmt.
The recom. dosage 150 mg×2/d admin. approx. 12 hrs. apart.
Caps. should be taken with food and swallowed whole with liquid.
Do not exceed the recom. max. dly. dosage of 300 mg.
Pts. with mild hep. impair. (Child Pugh A): 100mg×2/d. approx. 12 hrs. apart taken with food. See lit.
Tmt. of idiopathic pulmonary fibrosis (IPF) in adults.
Tmt. of chron. fibros. interstit. dis. (ILDs) with a progress. phenotype.
Syst. Sclerosis-Assoc. Interstit. Lung Dis.: indicated to slow the rate of decline in pulmon. func. in pts. with syst. sclerosis assoc. interstit. lung dis. (SSc-ILD).
C/I: Hypersens.